Abstract
Activated signaling through the small guanosine triphosphatase Ras is often associated with abnormal proliferation of cancer cells. Stites et al. used a combination of mathematical modeling and experiments to gain new insights into the regulatory properties of the network of factors that influence Ras (or are regulated by it) and how these factors are altered in cancer cells. Their results offer insight into why particular activating Ras mutants, but not others, are found in cancer cells, and suggest a pharmacological strategy that may preferentially impede excessive signaling in networks containing an oncogenically mutated form of Ras while sparing normal cells. E. C. Stites, P. C. Trampont, Z. Ma, K. S. Ravichandran, Network analysis of oncogenic Ras activation in cancer. Science 318 , 463-467 (2007). [Abstract] [Full Text]
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
